Could fewer radiation days be safer for myeloma patients?
NCT ID NCT06270888
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if a shorter course of radiation (hypofractionation) is safe for people with multiple myeloma who need pelvic radiation. Instead of the usual 2-3 weeks, the radiation is given over fewer days with slightly higher daily doses. The goal is to find the highest safe dose per session. About 30 adults with multiple myeloma will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Chicago Comprehensive Cancer Center
RECRUITINGChicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?
- A guided path back to work after blood cancer: a trial tests the impact